



**Scientific and Practical Conference
 “The VI Moscow International School of Young Scientists in
 Hematology named after S. P. Botkin”
 February 27–28, 2026**

Thematic Exhibition

Venue: Novotel Moscow City Hotel, 2 Presnenskaya Embankment, Moscow
 online broadcast at https://med-conferences.ru/vi_mihs

P R O G R A M

February 27th, 2026
08:00–18:50

Timing	Title	Speakers
07:15-16:00	REGISTRATION	
08:00-08:15	Opening ceremony of VI Moscow International School of Young Scientists in Hematology named after S.P. Botkin	Introductory remarks: Prof. Kulagin A.D., Prof. Nikitin E.A., Prof. Ptushkin V.V.
08:15-09:35	TRANSPLANTATION <i>Session Chairs: Prof. Alexandr Kulagin, Prof. Vadim Ptushkin</i>	
08:15-08:30	Comparison of Two GVHD Prophylaxis Platforms in Pediatric Allogeneic HSCT	Anna Vlasova, Regional Children's Clinical Hospital, Yekaterinburg, Russia
08:30-08:45	Autologous Stem Cell Transplantation Outcomes after Anti-PD-1 Treatment in Third and Subsequent Lines for Relapsed/Refractory Classical Hodgkin Lymphoma	Yulia Protopopova, Pirogov National Medical Surgical Center, Moscow, Russia
08:45-09:00	Predictors of hepatic veno-occlusive disease in children with acute leukemia after allogeneic hematopoietic stem cell transplantation following antibody-drug conjugate therapy	Zhemal Rakhmanova, Research Institute of Children's Oncology, Hematology and Transplantology n.a. R.M. Gorbacheva, St Petersburg, Russia
09:00-09:15	Optimization of Infection Prevention in Patients with Lymphoproliferative Diseases	Olga Gerasimovich, Minsk Scientific and Practical Center of Surgery, Transplantology and

	After Auto-HSCT Using Intravenous Immunoglobulin	Hematology, Minsk, Republic of Belarus
09:15-09:30	Maribavir for treatment of refractory/recurrent cytomegalovirus infection in allogeneic HSCT recipients	Aleksandr Sinyaev, Research Institute of Children's Oncology, Hematology and Transplantology n.a. R.M. Gorbacheva, St Petersburg, Russia
09:30-09:35	Discussion	
09:35-10:55	LYMPHOPROLIFERATIVE DISORDERS AND PLASMA CELL DISCRASIAS (PART 1). Session Chairs: Prof. Gayane Tumyan, Prof. Elena Baryakh, Dr. Lali Babicheva	
09:35-09:50	PET-Adapted Omission of Salvage Chemotherapy in Responders to Second-Line Nivolumab Monotherapy for Hodgkin Lymphoma (NCT04981899)	Polina Kotseliabina, Research Institute of Children's Oncology, Hematology and Transplantology n.a. R.M. Gorbacheva, St Petersburg, Russia
09:50-10:05	First-line immunochemotherapy for primary central nervous system lymphoma: Russian multicenter study	Vladislav Markelov, Research Institute of Children's Oncology, Hematology and Transplantology n.a. R.M. Gorbacheva, St Petersburg, Russia
10:05-10:20	The first experience with a new PD-1 inhibitor (prolgolimab) in the treatment of patients with relapsed/refractory classical Hodgkin's lymphoma.	Nikita Zemlyakov, N.I. Pirogov Russian National Research Medical University, Moscow, Russia
10:20-10:35	Features of HIV-associated diffuse large B-cell lymphoma and its treatment	Anastasia Galitsyna, A. Tsyba Medical Radiological Research Centre, Russia
10:35-10:50	Outcome of patients with T-cell/histiocyte-rich large B-cell lymphoma: A single institution series	Mohammed Alshehri, King Fahad Specialist Hospital, Dammam, Saudi Arabia
10:50-10:55	Discussion	
10:55-11:10	Break	
11:10-12:30	LYMPHOPROLIFERATIVE DISORDERS AND PLASMA CELL DISCRASIAS (PART 2) Session Chairs: Prof. Natalia Mikhailova, Prof. Elena Baryakh, Prof. Gayane Tumyan	
11:10-11:25	Active surveillance is a valid option for newly diagnosed nodular lymphocyte-predominant Hodgkin Lymphoma.	Reem Abdulla, King Fahad Specialist Hospital, Dammam, Saudi Arabia
11:25-11:40	A phase II study of lenalidomide, zanubrutinib plus obinutuzumab in patients with FLIPI2 high-risk newly diagnosed follicular lymphoma: An interim analysis	Ruichi Li, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, China
11:40-11:55	First experience with the R/G-BAC regimen for the treatment of patients with early relapsed or refractory follicular lymphoma	Vladimir Murzo, N.N. Blokhin National Medical Research Center of Oncology, Moscow, Russia

11:55-12:10	Residual tumor clone characteristics determined by multicolor flow cytometry and its correlation with prognosis in Waldenström's macroglobulinemia	Anastasia Vinnikova, National Medical Research Center of Hematology, Moscow, Russia
12:10-12:25	Clinical impact and prognostic implications of concurrent light-chain amyloidosis in patients with POEMS syndrome: a single-center retrospective study	Yuhan Bao, Tongji Medical College, China
12:25-12:30	Discussion	
12:30-12:45	Break	
12:45-14:05	ACUTE LEUKEMIA <i>Session Chairs: Prof. Vadim Ptushkin, Prof. Irina Lukyanova, Dr. Olga Alyoshina</i>	
12:45-13:00	Association of the rs4590952 allelic variants and 12q21.32 copy-neutral loss of heterozygosity with treatment resistance in acute lymphoblastic leukemias.	Abdulpatakh Abdulpatakhov, National Medical Research Center of Hematology, Moscow, Russia
13:00-13:15	Comparison of Azacitidine--Venetoclax and Intensive Salvage Chemotherapy in Transplant-Eligible Patients with Relapsed/Refractory AML After Intensive Induction	Georgiy Pikulin, Moscow Botkin Multidisciplinary Scientific-Clinical Center, Moscow, Russia
13:15-13:30	Venetoclax-based regimens as first-line treatment in adult patients with newly diagnosed poor cytogenetic risk AML. Single center experience	Nikita Pastukhov, Research Institute of Children's Oncology, Hematology and Transplantology n.a. R.M. Gorbacheva, St Petersburg, Russia
13:30-13:45	Comparative efficacy of ATRA-ATO induction therapy versus arsenic trioxide-free regimens in patients with acute promyelocytic leukemia	Artur Sarkisyan, Moscow Botkin Multidisciplinary Scientific-Clinical Center, Moscow, Russia
13:45-14:00	Diagnosis of acute lymphoblastic leukemia with CRLF2 rearrangements in children	Ivan Kotov, Ural State Medical University, Yekaterinburg, Russia
14:00-14:05	Discussion	
14:05-14:35	Break	
14:35-15:55	INNOVATIVE TECHNOLOGIES AND PRECISION APPROACHES IN HEMATOLOGY. <i>Session Chairs: Prof. Irina Lukyanova, Prof. Yajing Zhang, Prof. Marina Popova</i>	
14:35-14:50	A Clinical Risk Scoring System for the Prediction of Early Infection after CAR-T Therapy	An Ning, Tongji Medical College, China
14:50-15:05	Pharmacokinetic and pharmacodynamic characteristics of PGCT-002, a next-generation anti-CD19 CAR-T, in vitro and in vivo studies	Ivan Gaponenko, Research Institute of Children's Oncology, Hematology and Transplantology n.a. R.M. Gorbacheva, St Petersburg, Russia

15:05-15:20	Comparative efficacy and safety study of CCR5-Uco-hetTALEN mediated CCR5 gene knockout in CD34+ cells of healthy donors and patients with lymphoproliferative diseases and indications for autologous hematopoietic stem cell transplantation	Olga Kopteva, Research Institute of Children's Oncology, Hematology and Transplantology n.a. R.M. Gorbacheva, St Petersburg, Russia
15:20-15:35	Impact of Promoter Architecture on Lentiviral Transduction Efficiency in Human CD34+ Hematopoietic Stem Cells	Valeriia Laushkina, Research Institute of Children's Oncology, Hematology and Transplantology n.a. R.M. Gorbacheva, St Petersburg, Russia
15:35-15:50	Preclinical Development of a Novel Targeted Immune Checkpoint Inhibitor for AML and MDS	Evgeniya Platonova, I.P. Pavlov First Saint Petersburg State Medical University, Saint-Petersburg, Russia
15:50-15:55	Discussion	
15:55-16:05	Break	
16:05-17:20	CHRONIC MYELOPROLIFERATIVE DISORDERS AND MDS Session Chairs: Prof. Vasilyi Shuvaev, Prof. Elena Morozova, Prof. Olga Vinogradova	
16:05-16:20	Myelodysplastic Syndrome with Bone Marrow Fibrosis: Clinical and Laboratory Features and Treatment Outcomes	Iuliia Poliakova, Research Institute of Children's Oncology, Hematology and Transplantology n.a. R.M. Gorbacheva, St Petersburg, Russia
16:20-16:35	Factors influencing the achievement and duration of hematological response to lenalidomide in patients with myelodysplastic neoplasms with long arm deletion of chromosome 5	Valeriya Okhota, National Medical Research Center of Hematology, Moscow, Russia
16:35-16:50	Risk stratification for survival and leukemic transformation in myelodysplastic syndrome based on the pathogenicity assessment of TP53 mutations	Dmitrii Bug, Research Institute of Children's Oncology, Hematology and Transplantology n.a. R.M. Gorbacheva, St Petersburg, Russia
16:50-17:05	The frequency of detection of thrombophilia genes polymorphism in pregnancy complications	Nadehzda Kurkina, Mordovian State University named after N.P. Ogarev, Saransk, Russia
17:05-17:20	Clinical significance of somatic compensatory events in patients with Shwachman--Diamond syndrome	Nataliya Malyasova, Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology, and Immunology, Moscow, Russia
17:20-17:30	Winners' Award Ceremony	
17:30-17:50	Can we implement MOB-oriented therapy for multiple myeloma today?	Prof. Mohamad Mohty, Department of Hematology and Cell Therapy, Saint-Antoine

		Hospitals and Sorbonne University, Paris, France
17:50-18:50	AstraZeneca Satellite Symposium	
17.50-18.05	DLBCL: an aggressive adversary for the hematologist	L.G. Babicheva, Cand.Sc. (Medicine), RMANPO of Ministry of Health of Russia, Moscow, Russia
18.05-18.20	AL amyloidosis: the dangerous invisible threat of plasma cell dyscrasias	I.G. Rekhina, D.Sc. (Medicine), National Medical Research Center of Hematology, Moscow, Russia
18.20-18.35	What? Where? When? The role and timing of CAR-T cell therapy in the treatment of adult hematologic malignancies	O.A. Alyoshina, Cand.Sc. (Medicine), National Medical Research Center of Hematology, Moscow, Russia
18.35-18.50	Cellular immunoadoptive therapy for multiple myeloma	Prof. Vadim Ptushkin, Moscow Botkin Multidisciplinary Scientific-Clinical Center, Moscow, Russia

February 28th, 2026
08:00-18:40

08:00-10:20	Plenary session: CAR-T CELL TECHNOLOGIES AND AGGRESSIVE LYMPHOMAS <i>Session chairs: Prof. Yajing Zhang, Prof. Vadim Ptushkin</i>	
08:00-08:20	Modern standards of treatment for diffuse large B-cell lymphoma (DLBCL): first-line therapy	Prof. Ahmed Absi, King Abdulaziz Medical City, Ministry of National Guard Health Affairs, Jeddah, Saudi Arabia
08:20-08:40	Epcoritamab: A unified approach to the treatment of aggressive and indolent lymphoma	Prof. Gayane Tumyan, N.N. Blokhin National Medical Research Center of Oncology, Moscow, Russia
08:40-09:10	CAR-T Clinical Trials and Commercial Application in Lymphoma — Current Development Status and Management in China	Prof. Yuqin Song, Beijing Cancer Hospital, China
09:10-09:40	Targeting B-lineage Cells with CAR-T: A Strategy for Lymphoid Malignancies and Autoimmune Diseases	Prof. Yajing Zhang, Beijing Gobroad Boren Hospital, China
09:40-09:55	Multiple myeloma: bridging therapy before CAR-T and beyond	Prof. Vadim Ptushkin, Moscow Botkin Multidisciplinary Scientific-Clinical Center, Moscow, Russia
09:55-10:15	A prognostic organ-based classification and risk-stratified therapeutic framework	Wang, Xinran, Tongji Hospital of Tongji Medical College of

	for chronic active Epstein-Barr virus disease: a multinational cohort study of 765 patients	Huazhong University of Science and Technology, Wuhan, China
10:15-10:20	Discussion	
10:20-10:35	Break	
10:35-12:25	Plenary session: HEMOLYTIC ANEMIAS Session chairs: Prof. Alexander Kulagin, Prof. Eugene Nikitin	
10:35-10:50	Treatment of PNH: the experience of Botkin Hospital	Evgeniya Arshanskaya, Cand.Sc. (Medicine), Moscow Botkin Multidisciplinary Scientific-Clinical Center, Moscow, Russia
10:50-11:05	Iptacopan in real-world clinical practice. Results of the first year of PNH therapy	Prof. Kulagin Alexander, Research Institute of Children's Oncology, Hematology and Transplantology n.a. R.M. Gorbacheva, St Petersburg, Russia
11:05-11:20	Pegcetacoplan - a step beyond traditional complement inhibition	Prof. Vadim Ptushkin, Moscow Botkin Multidisciplinary Scientific-Clinical Center, Moscow, Russia
11:20-11:50	Breakthrough hemolysis in paroxysmal nocturnal hemoglobinuria (PNH)	Prof. Bruno Fattizzo, Università degli Studi di Milano, Italy
11:50-12:20	Autoimmune hemolytic anemias: state of art	Prof. Bruno Fattizzo, Università degli Studi di Milano, Italy
12:20-12:25	Discussion	
12:25-13:00	Break	
13:00-14:50	PLASMA CELL DISCRASIAS Session chairs: Prof. Vadim Ptushkin, Prof. Raymong Wong	
13:00-13:20	From smoldering myeloma to first-line quadruplets: a modern view of multiple myeloma therapy and the path to functional cure. Is MRD-guided treatment ready for widespread use?	Prof. Vadim Ptushkin, Moscow Botkin Multidisciplinary Scientific-Clinical Center, Moscow, Russia
13:20-13:45	Induction therapy with quadruplets in non-candidates for autologous HSCT: from RCTs to real-world clinical practice	Maksim Soloviev, Cand.Sc. (Medicine), National Medical Research Center of Hematology, Moscow, Russia
13:45-14:05	"Endless" opportunities and how to use them? What is the optimal treatment sequence?	Prof. Raymond Wong, Department of Medicine & Therapeutics, The Chinese University of Hong Kong
14:05-14:25	Immune Breakthrough: The Role of Bispecific Antibodies Today and Their Potential for Tomorrow	Maksim Soloviev, Cand.Sc. (Medicine), National Medical Research Center of Hematology, Moscow, Russia
14:25-14:45	The Alchemy of Proteins and Errors of Perception: How AL Amyloidosis Eludes the Hematologist	Olga Pirogova, Cand.Sc. (Medicine), Research Institute of Children's Oncology, Hematology and Transplantology n.a. R.M. Gorbacheva, St Petersburg, Russia
14:45-14:50	Discussion	

14:50-15:10	Break	
15:10-16:50	Plenary session: ACUTE LEUKEMIA AND MYELODISPLASTIC SYNDROMES <i>Session chairs: Prof. Vadim Ptushkin, Dr. Olga Alyoshina,</i>	
15:10-15:30	Pegaspargase in the Treatment of Adult ALL: Russian and Global Experience	Dr. Olga Alyoshina, Cand.Sc. (Medicine), National Medical Research Center of Hematology, Moscow, Russia
15:30-15:45	Treatment of FLT3-positive AML: from induction to maintenance	Dr. Julia Kruchinkina, Cand.Sc. (Medicine), Moscow Botkin Multidisciplinary Scientific-Clinical Center, Moscow, Russia
15:45-16:05	IDH1 as a Therapeutic Anchor: New Treatment Opportunities in Acute Myeloid Leukemia (AML)	Prof. Vadim Ptushkin, Moscow Botkin Multidisciplinary Scientific-Clinical Center, Moscow, Russia (<i>supported by</i>
16:05-16:30	Treatment of transplant ineligible AML patients	Prof. Courtney DiNardo, MD Anderson Cancer Center, The University of Texas at Houston, Houston, USA
16:30-16:45	Response to tyrosine kinase inhibitor therapy in patients with chronic lymphocytic leukemia. How can it be modulated?	Prof. Anna Turkina, National Medical Research Center of Hematology, Moscow, Russia
16:45-16:50	Discussion	
16:50-17:05	Break	
17:05-18:40	Plenary session: CHRONIC LYMPHOCYTIC LEUKEMIA AND INDOLENT LYMPHOMAS <i>Session chairs: Prof. Grigory Tsaur, Prof. Eugene Nikitin, Prof. Kamil Kaplanov</i>	
17:05-18:05	AbbVie Satellite Symposium CORRECT AND TIMELY DIAGNOSIS AS THE KEY TO SUCCESS IN MODERN THERAPY OF PATIENTS WITH CLL	
17:05-17:25	Молекулярно-генетическая диагностика хронического лимфолейкоза (ХЛЛ): современные подходы и перспективные технологии будущего	Grigory Tsaur, D.Sc. (Medicine), Regional Children's Clinical Hospital, Yekaterinburg, Russia
17:25-17:45	Is there a role for fixed-duration targeted therapy regimens in the most prognostically unfavorable patient subgroups?	Maria Ivanova, Cand.Sc. (Medicine), Consultative and Diagnostic Center (CDC), I.P. Pavlov First Saint Petersburg State Medical University, Saint-Petersburg, Russia
17:45-18:05	Features of high-risk CLL therapy in real clinical practice	Maria Kislova, Moscow Botkin Multidisciplinary Scientific-Clinical Center, Moscow, Russia
18:05-18:20	Modern approaches to the treatment of chronic lymphocytic leukemia: from tradition to innovation.	Prof. Eugene Nikitin, Moscow Botkin Multidisciplinary Scientific-Clinical Center, Moscow, Russia
18:20-18:35	First-line treatment of mantle cell lymphoma: current challenges and the role of innovative regimens in clinical guidelines	Kamil Kaplanov, D.Sc. (Medicine), Moscow Botkin Multidisciplinary

		Scientific-Clinical Center, Moscow, Russia
18:35-18:40	Discussion and conclusion of the conference	